Exicure is a clinical stage public biopharmaceutical company developing a new class of drugs. The company has a unique and highly differentiated delivery platform for oligonucleotide (RNA and DNA) based therapies. Instead of focusing like other DNA/RNA based companies on delivery to the liver, Exicure’s unique technology enables oligonucleotide delivery to a broad range of diseased tissues in addition to the liver. Exicure is developing treatments that directly target organs such as the brain, eyes, skin and gut via local delivery, preventing toxic effects often associated with systemic delivery. Exicure is a VIPE (Venture Investment in Public Equity) and is listed on Nasdaq

LocationChicago, IL
CEODavid Giljohann
Partner Bali Muralidhar
Websitewww.exicuretx.com